NeuroPace director granted shares and options

NeuroPace Inc director R Scott Huennekens received new equity awards as compensation.

Rhea-AI Filing Summary

NeuroPace Inc director R Scott Huennekens received new equity awards as compensation. He was granted 2,890 shares of Common Stock and a stock option for 5,368 shares at an exercise price of $15.74 per share.

The 2,890 shares will vest in twelve equal monthly installments, and the 5,368 option shares will also vest in twelve equal monthly installments, in each case conditioned on his continuous service through each vesting date. Following these awards, he holds 2,890 Common shares and 5,368 option shares directly.

Insider Trade Summary

Grant/Award: 8,258 shares

Grant/Award 2 txns

Insider Huennekens R Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,368	$0.00	$0.00
Grant/Award	Common Stock	2,890	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,368 contracts (Direct); Common Stock — 2,890 shares (Direct)

Footnotes (2)

1. F1. The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.
2. F2. The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Restricted share grant: 2,890 shares Stock option grant size: 5,368 shares Option exercise price: $15.74 per share +3 more

6 metrics

Restricted share grant 2,890 shares Common Stock awarded to director as compensation

Stock option grant size 5,368 shares Underlying NeuroPace Common Stock subject to option

Option exercise price $15.74 per share Strike price for director stock option

Option expiration June 4, 2036 Expiration date of stock option grant

Shares held after grant 2,890 shares Total NeuroPace Common Stock directly held post‑transaction

Options held after grant 5,368 option shares Total option shares directly held post‑transaction

Key Terms

Stock Option (Right to Buy), vesting, continuous service, exercise price

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 5,368 underlying shares at $15.74"

vesting financial

"The shares shall vest in twelve equal consecutive monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service through each vesting date"

exercise price financial

"conversion_or_exercise_price: 15.7400 per share for the option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NeuroPace (NPCE) disclose for R Scott Huennekens?

NeuroPace reported that director R Scott Huennekens received equity awards, not an open‑market trade. He was granted 2,890 shares of Common Stock and a stock option covering 5,368 shares as part of his compensation package.

How many NeuroPace (NPCE) shares and options were granted to R Scott Huennekens?

Huennekens was granted 2,890 shares of Common Stock and a stock option on 5,368 shares. These awards increase his direct equity exposure to NeuroPace through both outright share ownership and future purchase rights.

What is the exercise price and term of R Scott Huennekens’ NeuroPace stock option?

The stock option granted to Huennekens covers 5,368 shares at an exercise price of $15.74 per share. The option is scheduled to expire on June 4, 2036, providing a long-dated right to buy NeuroPace common stock.

How do the new NeuroPace equity awards vest for R Scott Huennekens?

Both the 2,890 restricted shares and the 5,368 option shares vest in twelve equal monthly installments. Each installment requires Huennekens to maintain continuous service with NeuroPace through the applicable vesting date before those shares or options are fully earned.

Is R Scott Huennekens’ NeuroPace Form 4 a stock purchase or a compensation grant?

The Form 4 reflects compensation grants, not an open‑market stock purchase. The transactions are coded as awards, delivering restricted shares and options that vest over time rather than immediate buying or selling of NeuroPace stock in the market.

What are R Scott Huennekens’ NeuroPace holdings after this Form 4 transaction?

After these awards, Huennekens directly holds 2,890 shares of NeuroPace Common Stock and a stock option covering 5,368 shares. These positions reflect his equity stake linked to continued board service and the vesting schedule disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huennekens R Scott

(Last) (First) (Middle)

C/O NEUROPACE, INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW CALIFORNIA 94043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		2,890(1)	A	$0	2,890	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.74	06/05/2026		A		5,368		(2)	06/04/2036	Common Stock	5,368	$0	5,368	D

Explanation of Responses:

1. The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.

2. The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)